Charles River Laboratories (CRL) Tops Q1 EPS by 19c; raises guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $283.28 -1.81%
Revenue Growth %: -4.3%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.78, $0.19 better than the analyst estimate of $2.59. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $986.31 million.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $9.90-$10.90, versus the consensus of $10.24.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
- HSBC Raises S&P500 Target to 8,100
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
